Groundbreaking Bowel Cancer Trial Had Zero Relapses for Patients After 33 Months

Key Points:

• A clinical trial led by University College London found that administering the immunotherapy drug pembrolizumab before surgery significantly improved survival rates for patients with stage 2 or 3 bowel cancer, with no cancer recurrence observed nearly three years post-treatment.
• The NEOPRISM-CRC trial involved 32 patients with MMR deficient/MSI-high bowel cancer, showing that 59% had no signs of disease after treatment, and all treated patients remained cancer-free after 33 months.
• Personalized blood tests and immune profiling were developed to predict treatment response early and identify patients who may need tailored therapy, enhancing the potential for more precise and effective treatment plans.
• This approach contrasts with the standard treatment of surgery followed by chemotherapy, which typically sees about 25% of patients relapse within three years, suggesting immunotherapy before surgery offers more durable cancer control.
• Bowel cancer remains a major health issue, being the fourth most common cancer in the UK and a leading cause of cancer-related death in the US, particularly affecting younger adults under 50, highlighting the importance of improved treatment strategies.